Advocacy group's advisory board members defect over Alzheimer's drug – STAT

Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Ed Silverman April 7, 2022
The furious debate over Biogen’s Alzheimer’s treatment has now sparked controversy at the Alliance for Aging Research, an advocacy group that has seen half of its scientific advisory board members resign after learning the organization had lobbied against a Medicare proposal to restrict coverage of the medication.
The resignations by nine of 17 board members followed a rally the organization held last month in front of the Centers for Medicare & Medicaid Services offices to protest a preliminary decision concerning the Alzheimer’s treatment. The advocacy group is upset that the agency proposed paying only for patients enrolled in clinical trials, a decision the agency confirmed in its final ruling Thursday
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Pharmalot Columnist, Senior Writer
Ed covers the pharmaceutical industry.
drug development
STAT+
This name will appear with your comment
There was an error saving your display name. Please check and try again.
By Ed Silverman
By Adam Feuerstein
advertisement
By Bob Herman
By Ed Silverman
By Lev Facher
Reporting from the frontiers of health and medicine

source